Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and relapsers.Material and methods. Analysis of the cost...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Format: Artigo
Jezik:Russo
Izdano: Journal Infectology 2016-11-01
Serija:Žurnal Infektologii
Teme:
chronic hepatitis c
naive patients
relapse
simeprevir
narlaprevir
cost-effectiveness
Online dostop:https://journal.niidi.ru/jofin/article/view/514
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki